- Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
- BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27
- NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018
- Apricus Biosciences Receives Complete Response Letter from FDA for Vitarosâ„¢
- Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
- Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
- Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
- Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
- JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer
- Sodium Acetate Market worth $220mn by 2024: Global Market Insights, Inc.
|"PMN's PMN310 demonstrated a positive signal for better efficacy."|
|"VIVE intends to expand its CMRF platform into a new market."|
|"VIVE expects to forge ahead with stress urinary incontinence studies."|